previously untreated patients with acute nonlymphocytic leukemia ( anll ) aged 15 to 70 years were randomized to either cytosine arabinoside 100 mg/m2/d continuous intravenous ( iv ) infusion days 1 through 7 , daunorubicin 50 mg/m2/d iv days 1 through 3 ( 7-3 ) , or the same drugs intensified with etoposide 75 mg/m2/d iv days 1 through 7 ( 7-3-7 ) as induction therapy .
C0023467
acute nonlymphocytic leukemia
C0015133
etoposide